LZTFL1 and nonpapillary renal cell carcinoma: We established a PDX model with fresh ccRCC tissue and evaluated the effect of LZTFL1-targeted cancer therapy via intra-tumoral injection of lentiviruses expressing LZTFL1 (twice weekly, for a total of 10 times).